Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BNTX
stocks logo

BNTX

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
136.87M
+6.35%
-2.588
-22.98%
763.27M
-38.68%
-0.576
-171.12%
951.45M
-20.05%
-0.853
-178.95%
Estimates Revision
The market is revising Downward the revenue expectations for BioNTech SE (BNTX) for FY2025, with the revenue forecasts being adjusted by -16.56% over the past three months. During the same period, the stock price has changed by -13.07%.
Revenue Estimates for FY2025
Revise Downward
down Image
-16.56%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+47.18%
In Past 3 Month
Stock Price
Go Down
down Image
-13.07%
In Past 3 Month
17 Analyst Rating
up Image0
Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 141.53 USD with a low forecast of 110.00 USD and a high forecast of 171.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
3 Hold
0 Sell
Strong Buy
up Image0
Current: 97.270
sliders
Low
110.00
Averages
141.53
High
171.00
up Image0
Current: 97.270
sliders
Low
110.00
Averages
141.53
High
171.00
HC Wainwright & Co.
Robert Burns
Strong Buy
Maintains
$150 → $145
2025-04-01
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$150 → $145
2025-04-01
Maintains
Strong Buy
Reason
Citigroup
Geoff Meacham
Strong Buy
Initiates
$145
2025-03-13
Reason
Citigroup
Geoff Meacham
Price Target
$145
2025-03-13
Initiates
Strong Buy
Reason
Citi analyst Geoff Meacham initiated coverage of BioNTech with a Buy rating and $145 price target. Healthcare policy remains a key biopharma sector uncertainty but major economic worries have underscored the defensive attributes of biotech, the analyst tells investors in a research note. The firm says that despite near-term "choppiness," a "barbell approach" to the sector still makes sense with higher-growth large caps likely able to absorb potential policy headwinds and catalyst-driven small-cap biotechs being insulated from macro uncertainties. Citi's preferred smaller caps are focused on unmet medical needs, have differentiated research and development platforms or are "clean growth stories." The firm highlights Apogee, Avidity, and Kymera as favorites.
BMO Capital
Etzer Darout
Buy
Maintains
$130 → $143
2025-03-11
Reason
BMO Capital
Etzer Darout
Price Target
$130 → $143
2025-03-11
Maintains
Buy
Reason
Canaccord Genuity
John Newman
Strong Buy
Maintains
$171
2025-03-11
Reason
Canaccord Genuity
John Newman
Price Target
$171
2025-03-11
Maintains
Strong Buy
Reason
Morgan Stanley
Terence Flynn
Buy
Maintains
$145 → $139
2025-03-11
Reason
Morgan Stanley
Terence Flynn
Price Target
$145 → $139
2025-03-11
Maintains
Buy
Reason
Truist Securities
Asthika Goonewardene
Strong Buy
Initiates
$172
2025-01-10
Reason
Truist Securities
Asthika Goonewardene
Price Target
$172
2025-01-10
Initiates
Strong Buy
Reason
Truist initiated coverage of BioNTech with a Buy rating and $172 price target. BioNTech is an oncology company "at heart, even though it was the COVID vaccine that made it a household name," the analyst tells investors in a research note. The firm says that with the pandemic in the rear-view mirror, investor focus is increasingly shifting to BioNTech's oncology business. It says 2025 is set up with potentially stock-moving read-outs for key assets, presenting "ample opportunity" for BioNTech to grow into the price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Biontech SE (BNTX.O) is -13.64, compared to its 5-year average forward P/E of -3.01. For a more detailed relative valuation and DCF analysis to assess Biontech SE 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.01
Current PE
-13.64
Overvalued PE
5.85
Undervalued PE
-11.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
4.57
Current EV/EBITDA
-4.39
Overvalued EV/EBITDA
13.91
Undervalued EV/EBITDA
-4.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
5.74
Current PS
8.47
Overvalued PS
8.57
Undervalued PS
2.90

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 4006.05% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

BNTX News & Events

Events Timeline

(ET)
2025-05-07
05:57:56
Prasad appointment not necessarily bad news for biopharma, says Citi
select
2025-05-05 (ET)
2025-05-05
06:46:39
BioNTech reports Q1 EPS EUR (1.73) vs. EUR (1.31) last year
select
2025-05-05
06:33:56
BioNTech names Ramon Zapata as CFO, succeeding Jens Holstein
select
Sign Up For More Events
Sign Up For More Events

News

Preview
2.0
05-07NASDAQ.COM
Why BioNTech Stock Got Trounced on Tuesday

  • BioNTech Stock Decline: BioNTech's shares fell over 6% following concerns about a new FDA appointment and a bearish analyst report, contrasting with the S&P 500's minor drop of 0.8%.

  • Analyst Insights: Citigroup's Geoff Meacham lowered BioNTech's price target from $145 to $140, citing uncertainty in U.S. respiratory vaccine policy despite acknowledging the company's strong first-quarter performance and potential for future products.

Preview
9.5
05-06Yahoo Finance
BioNTech SE (BNTX) Q1 2025 Earnings Call Highlights: Navigating Challenges and Advancing ...

  • Financial Performance Overview: BioNTech SE reported a total revenue of EUR183 million in Q1 2025, a slight decrease from the previous year, with a net loss of EUR416 million and increased R&D expenses. The company maintains strong cash reserves of EUR15.9 billion.

  • Oncology Program Developments: BioNTech is advancing its oncology programs, including plans for BLA submission for BNT323 by the end of 2025, while also preparing to launch a variant-adapted COVID-19 vaccine, indicating ongoing leadership in both cancer treatment and COVID-19 vaccination markets.

Preview
5.0
05-06Benzinga
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion

  • Financial Performance: BioNTech reported a first-quarter loss of $1.82 per share, with sales of $192.23 million, both figures beating market expectations. The company aims to evolve into a leading biotech firm focused on oncology by 2030.

  • Leadership Change and Future Guidance: Ramón Zapata-Gomez will become CFO effective July 1, 2025, succeeding Jens Holstein. BioNTech reaffirmed its revenue guidance for 2025, anticipating stable vaccination rates and potential impacts from external factors on revenues.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Biontech SE (BNTX) stock price today?

The current price of BNTX is 97.27 USD — it has increased 4.85 % in the last trading day.

arrow icon

What is Biontech SE (BNTX)'s business?

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

arrow icon

What is the price predicton of BNTX Stock?

Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 141.53 USD with a low forecast of 110.00 USD and a high forecast of 171.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Biontech SE (BNTX)'s revenue for the last quarter?

Biontech SE revenue for the last quarter amounts to 182.80M USD, decreased -2.56 % YoY.

arrow icon

What is Biontech SE (BNTX)'s earnings per share (EPS) for the last quarter?

Biontech SE. EPS for the last quarter amounts to -1.73 USD, increased 32.06 % YoY.

arrow icon

What changes have occurred in the market's expectations for Biontech SE (BNTX)'s fundamentals?

The market is revising Downward the revenue expectations for BioNTech SE (BNTX) for FY2025, with the revenue forecasts being adjusted by -16.56% over the past three months. During the same period, the stock price has changed by -13.07%.
arrow icon

How many employees does Biontech SE (BNTX). have?

Biontech SE (BNTX) has 6133 emplpoyees as of May 13 2025.

arrow icon

What is Biontech SE (BNTX) market cap?

Today BNTX has the market capitalization of 23.38B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free